Applications of CRISPR technology in cellular immunotherapy.
CRISPR
T-cell therapy
genomic perturbation
immune engineering
Journal
Immunological reviews
ISSN: 1600-065X
Titre abrégé: Immunol Rev
Pays: England
ID NLM: 7702118
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
17
05
2023
accepted:
07
06
2023
medline:
27
11
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
ppublish
Résumé
CRISPR technology has transformed multiple fields, including cancer and immunology. CRISPR-based gene editing and screening empowers direct genomic manipulation of immune cells, opening doors to unbiased functional genetic screens. These screens aid in the discovery of novel factors that regulate and reprogram immune responses, offering novel drug targets. The engineering of immune cells using CRISPR has sparked a transformation in the cellular immunotherapy field, resulting in a multitude of ongoing clinical trials. In this review, we discuss the development and applications of CRISPR and related gene editing technologies in immune cells, focusing on functional genomics screening, gene editing-based cell therapies, as well as future directions in this rapidly advancing field.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
199-216Subventions
Organisme : NIH HHS
ID : DP2CA238295
Pays : United States
Organisme : NIH HHS
ID : R01CA231112
Pays : United States
Organisme : NIH HHS
ID : T32GM007499
Pays : United States
Organisme : NIH HHS
ID : DP2CA238295
Pays : United States
Organisme : NIH HHS
ID : R01CA231112
Pays : United States
Organisme : NIH HHS
ID : T32GM007499
Pays : United States
Organisme : Cancer Research Institute
ID : CRI4964
Pays : United States
Informations de copyright
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Karginov FV, Hannon GJ. The CRISPR system: small RNA-guided defense in bacteria and archaea. Mol Cell. 2010;37:7-19. doi:10.1016/j.molcel.2009.12.033
Koonin EV, Makarova KS, Zhang F. Diversity, classification and evolution of CRISPR-Cas systems. Curr Opin Microbiol. 2017;37:67-78. doi:10.1016/j.mib.2017.05.008
Makarova KS, Wolf YI, Iranzo J, et al. Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants. Nat Rev Microbiol. 2020;18:67-83. doi:10.1038/s41579-019-0299-x
Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819-823. doi:10.1126/science.1231143
Mali P, Aach J, Stranges PB, et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol. 2013;31:833-838. doi:10.1038/nbt.2675
Barrangou R, Doudna JA. Applications of CRISPR technologies in research and beyond. Nat Biotechnol. 2016;34:933-941. doi:10.1038/nbt.3659
Pickar-Oliver A, Gersbach CA. The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol. 2019;20:490-507. doi:10.1038/s41580-019-0131-5
Knott GJ, Doudna JA. CRISPR-Cas guides the future of genetic engineering. Science. 2018;361:866-869. doi:10.1126/science.aat5011
Konermann S, Brigham MD, Trevino AE, et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature. 2015;517:583-588. doi:10.1038/nature14136
Zhou H, Liu J, Zhou C, et al. In vivo simultaneous transcriptional activation of multiple genes in the brain using CRISPR-dCas9-activator transgenic mice. Nat Neurosci. 2018;21:440-446. doi:10.1038/s41593-017-0060-6
Alerasool N, Segal D, Lee H, Taipale M. An efficient KRAB domain for CRISPRi applications in human cells. Nat Methods. 2020;17:1093-1096. doi:10.1038/s41592-020-0966-x
Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533:420-424. doi:10.1038/nature17946
Anzalone AV, Randolph PB, Davis JR, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576:149-157. doi:10.1038/s41586-019-1711-4
Chen S, Sanjana NE, Zheng K, et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell. 2015;160:1246-1260. doi:10.1016/j.cell.2015.02.038
Dong MB, Tang K, Zhou X, Zhou JJ, Chen S. Tumor immunology CRISPR screening: present, past, and future. Trends Cancer. 2022;8:210-225. doi:10.1016/j.trecan.2021.11.009
Dong MB, Wang G, Chow RD, et al. Systematic immunotherapy target discovery using genome-scale in vivo CRISPR screens in CD8 T cells. Cell. 2019;178:1189-1204.e1123. doi:10.1016/j.cell.2019.07.044
Schmidt R, Steinhart Z, Layeghi M, et al. CRISPR activation and interference screens decode stimulation responses in primary human T cells. Science. 2022;375:eabj4008. doi:10.1126/science.abj4008
Larson RC, Kann MC, Bailey SR, et al. CAR T cell killing requires the IFNgammaR pathway in solid but not liquid tumours. Nature. 2022;604:563-570. doi:10.1038/s41586-022-04585-5
Chow RD, Chen S. Cancer CRISPR screens in vivo. Trends Cancer. 2018;4:349-358. doi:10.1016/j.trecan.2018.03.002
Doench JG, Fusi N, Sullender M, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016;34:184-191. doi:10.1038/nbt.3437
Sanson KR, Hanna RE, Hegde M, et al. Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities. Nat Commun. 2018;9:5416. doi:10.1038/s41467-018-07901-8
Wang T, Birsoy K, Hughes NW, et al. Identification and characterization of essential genes in the human genome. Science. 2015;350:1096-1101. doi:10.1126/science.aac7041
DeWeirdt PC, Sangree AK, Hanna RE, et al. Genetic screens in isogenic mammalian cell lines without single cell cloning. Nat Commun. 2020;11:752. doi:10.1038/s41467-020-14620-6
Allen F, Behan F, Khodak A, et al. JACKS: joint analysis of CRISPR/Cas9 knockout screens. Genome Res. 2019;29:464-471. doi:10.1101/gr.238923.118
Legut M, Gajic Z, Guarino M, et al. A genome-scale screen for synthetic drivers of T cell proliferation. Nature. 2022;603:728-735. doi:10.1038/s41586-022-04494-7
Joung J, Ma S, Tay T, et al. A transcription factor atlas of directed differentiation. Cell. 2023;186:209-229.e226. doi:10.1016/j.cell.2022.11.026
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674. doi:10.1016/j.cell.2011.02.013
Shang W, Jiang Y, Boettcher M, et al. Genome-wide CRISPR screen identifies FAM49B as a key regulator of actin dynamics and T cell activation. Proc Natl Acad Sci U S A. 2018;115:E4051-E4060. doi:10.1073/pnas.1801340115
Gurusamy D, Henning AN, Yamamoto TN, et al. Multi-phenotype CRISPR-Cas9 screen identifies p38 kinase as a target for adoptive immunotherapies. Cancer Cell. 2020;37:818-833.e819. doi:10.1016/j.ccell.2020.05.004
Ye L, Park JJ, Peng L, et al. A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metab. 2022;34:595-614.e514. doi:10.1016/j.cmet.2022.02.009
Dixit A, Parnas O, Li B, et al. Perturb-Seq: dissecting molecular circuits with scalable single-cell RNA profiling of pooled genetic screens. Cell. 2016;167:1853-1866.e1817. doi:10.1016/j.cell.2016.11.038
Jaitin DA, Weiner A, Yofe I, et al. Dissecting immune circuits by linking CRISPR-pooled screens with single-cell RNA-Seq. Cell. 2016;167:1883-1896.e1815. doi:10.1016/j.cell.2016.11.039
Xie S, Duan J, Li B, Zhou P, Hon GC. Multiplexed engineering and analysis of combinatorial enhancer activity in single cells. Mol Cell. 2017;66:285-299.e285. doi:10.1016/j.molcel.2017.03.007
Datlinger P, Rendeiro AF, Schmidl C, et al. Pooled CRISPR screening with single-cell transcriptome readout. Nat Methods. 2017;14:297-301. doi:10.1038/nmeth.4177
Belk JA, Yao W, Ly N, et al. Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. Cancer Cell. 2022;40:768-786.e767. doi:10.1016/j.ccell.2022.06.001
Frangieh CJ, Melms JC, Thakore PI, et al. Multimodal pooled perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion. Nat Genet. 2021;53:332-341. doi:10.1038/s41588-021-00779-1
Shifrut E, Carnevale J, Tobin V, et al. Genome-wide CRISPR screens in primary human T cells reveal key regulators of immune function. Cell. 2018;175:1958-1971.e1915. doi:10.1016/j.cell.2018.10.024
Li W, Köster J, Xu H, et al. Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR. Genome Biol. 2015;16:281. doi:10.1186/s13059-015-0843-6
Li W, Xu H, Xiao T, et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 2014;15:554. doi:10.1186/s13059-014-0554-4
Dai X, Park JJ, du Y, et al. Massively parallel knock-in engineering of human T cells. Nat Biotechnol. 2023. doi:10.1038/s41587-022-01639-x
Codina A, Renauer PA, Wang G, et al. Convergent identification and interrogation of tumor-intrinsic factors that modulate cancer immunity In vivo. Cell Syst. 2019;8:136-151.e137. doi:10.1016/j.cels.2019.01.004
Chow RD, Guzman CD, Wang G, et al. AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma. Nat Neurosci. 2017;20:1329-1341. doi:10.1038/nn.4620
Wang G, Chow RD, Zhu L, et al. CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade. Cancer Discov. 2020;10:1912-1933. doi:10.1158/2159-8290.CD-19-1448
Wang G, Chow RD, Bai Z, et al. Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. Nat Immunol. 2019;20:1494-1505. doi:10.1038/s41590-019-0500-4
Zhang F, Guangchuan W, Chow R, et al. Multiplexed inhibition of immunosuppressive genes with Cas13d for on-demand combinatorial cancer immunotherapy. bioRxiv. 2023. doi:10.1101/2023.03.14.532668
Ye L, Park JJ, Dong MB, et al. In vivo CRISPR screening in CD8 T cells with AAV-sleeping beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma. Nat Biotechnol. 2019;37:1302-1313. doi:10.1038/s41587-019-0246-4
Wei J, Long L, Zheng W, et al. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature. 2019;576:471-476. doi:10.1038/s41586-019-1821-z
Chen Z, Arai E, Khan O, et al. In vivo CD8(+) T cell CRISPR screening reveals control by Fli1 in infection and cancer. Cell. 2021;184:1262-1280.e1222. doi:10.1016/j.cell.2021.02.019
Huang H, Zhou P, Wei J, et al. In vivo CRISPR screening reveals nutrient signaling processes underpinning CD8(+) T cell fate decisions. Cell. 2021;184:1245-1261.e1221. doi:10.1016/j.cell.2021.02.021
Maddineni S, Silberstein JL, Sunwoo JB. Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells. J Immunother Cancer. 2022;10:e004693. doi:10.1136/jitc-2022-004693
Ben-Shmuel A, Biber G, Barda-Saad M. Unleashing natural killer cells in the tumor microenvironment-the next generation of immunotherapy? Front Immunol. 2020;11:275. doi:10.3389/fimmu.2020.00275
Peterson EE, Barry KC. The natural killer-dendritic cell immune axis in anti-cancer immunity and immunotherapy. Front Immunol. 2020;11:621254. doi:10.3389/fimmu.2020.621254
Kloss M, Decker P, Baltz KM, et al. Interaction of monocytes with NK cells upon toll-like receptor-induced expression of the NKG2D ligand MICA. J Immunol. 2008;181:6711-6719. doi:10.4049/jimmunol.181.10.6711
Krebs P, Barnes MJ, Lampe K, et al. NK-cell-mediated killing of target cells triggers robust antigen-specific T-cell-mediated and humoral responses. Blood. 2009;113:6593-6602. doi:10.1182/blood-2009-01-201467
Laouar Y, Sutterwala FS, Gorelik L, Flavell RA. Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat Immunol. 2005;6:600-607. doi:10.1038/ni1197
Gao N, Schwartzberg P, Wilder JA, Blazar BR, Yuan D. B cell induction of IL-13 expression in NK cells: role of CD244 and SLAM-associated protein. J Immunol. 2006;176:2758-2764. doi:10.4049/jimmunol.176.5.2758
Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19:200-218. doi:10.1038/s41573-019-0052-1
Peng L, Renauer PA, Ye L, et al. Perturbomics of tumor-infiltrating NK cells. bioRxiv. 2023. doi:10.1101/2023.03.14.532653
Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581-590. doi:10.1038/nm.3838
Bock C, Datlinger P, Chardon F, et al. High-content CRISPR screening. Nat Rev Method Prime. 2022;2:8. doi:10.1038/s43586-021-00093-4
Fix SM, Jazaeri AA, Hwu P. Applications of CRISPR genome editing to advance the next generation of adoptive cell therapies for cancer. Cancer Discov. 2021;11:560-574. doi:10.1158/2159-8290.CD-20-1083
Barrett DM, Grupp SA, June CH. Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street. J Immunol. 2015;195:755-761. doi:10.4049/jimmunol.1500751
Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol. 2002;2:512-519. doi:10.1038/nri841
June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361-1365. doi:10.1126/science.aar6711
Moretti A, Ponzo M, Nicolette CA, Tcherepanova IY, Biondi A, Magnani CF. The past, present, and future of non-viral CAR T cells. Front Immunol. 2022;13:867013. doi:10.3389/fimmu.2022.867013
Zhou X, Cao H, Fang SY, et al. CTLA-4 tail fusion enhances CAR-T anti-tumor immunity. bioRxiv. 2023. doi:10.1101/2023.03.14.532655
Roth TL, Li PJ, Blaeschke F, et al. Pooled Knockin targeting for genome engineering of cellular immunotherapies. Cell. 2020;181:728-744.e721. doi:10.1016/j.cell.2020.03.039
Modlich U, Navarro S, Zychlinski D, et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther. 2009;17:1919-1928. doi:10.1038/mt.2009.179
He X, Tan C, Wang F, et al. Knock-in of large reporter genes in human cells via CRISPR/Cas9-induced homology-dependent and independent DNA repair. Nucleic Acids Res. 2016;44:e85. doi:10.1093/nar/gkw064
Ruggiero E, Carnevale E, Prodeus A, et al. CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function. Sci Transl Med. 2022;14:eabg8027. doi:10.1126/scitranslmed.abg8027
Dai X, Park JJ, du Y, et al. One-step generation of modular CAR-T cells with AAV-Cpf1. Nat Methods. 2019;16:247-254. doi:10.1038/s41592-019-0329-7
Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543:113-117. doi:10.1038/nature21405
Hanlon KS, Kleinstiver BP, Garcia SP, et al. High levels of AAV vector integration into CRISPR-induced DNA breaks. Nat Commun. 2019;10:4439. doi:10.1038/s41467-019-12449-2
Colella P, Ronzitti G, Mingozzi F. Emerging issues in AAV-mediated In vivo gene therapy. Mol Ther Methods Clin Dev. 2018;8:87-104. doi:10.1016/j.omtm.2017.11.007
Chavez M, Rane DA, Chen X, Qi LS. Stable expression of large transgenes via the knock-in of an integrase-deficient lentivirus. Nat Biomed Eng. 2023;7:661-671. doi:10.1038/s41551-023-01037-x
Schumann K, Lin S, Boyer E, et al. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci U S A. 2015;112:10437-10442. doi:10.1073/pnas.1512503112
Roth TL, Puig-Saus C, Yu R, et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature. 2018;559:405-409. doi:10.1038/s41586-018-0326-5
Oh SA, Senger K, Madireddi S, et al. High-efficiency nonviral CRISPR/Cas9-mediated gene editing of human T cells using plasmid donor DNA. J Exp Med. 2022;219:e20211530. doi:10.1084/jem.20211530
Foy SP, Jacoby K, Bota DA, et al. Non-viral precision T cell receptor replacement for personalized cell therapy. Nature. 2023;615:687-696. doi:10.1038/s41586-022-05531-1
Zhang Z, Qiu S, Zhang X, Chen W. Optimized DNA electroporation for primary human T cell engineering. BMC Biotechnol. 2018;18:4. doi:10.1186/s12896-018-0419-0
Hornung V, Latz E. Intracellular DNA recognition. Nat Rev Immunol. 2010;10:123-130. doi:10.1038/nri2690
Suzuki K, Mori A, Ishii KJ, et al. Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides. Proc Natl Acad Sci U S A. 1999;96:2285-2290. doi:10.1073/pnas.96.5.2285
Zhang J, Hu Y, Yang J, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature. 2022;609:369-374. doi:10.1038/s41586-022-05140-y
Zhang Z, Baxter AE, Ren D, et al. Efficient engineering of human and mouse primary cells using peptide-assisted genome editing. Nat Biotechnol. 2023. doi:10.1038/s41587-023-01756-1
Smith TT, Stephan SB, Moffett HF, et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol. 2017;12:813-820. doi:10.1038/nnano.2017.57
Tang L, Zheng Y, Melo MB, et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat Biotechnol. 2018;36:707-716. doi:10.1038/nbt.4181
Rurik JG, Tombácz I, Yadegari A, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375:91-96. doi:10.1126/science.abm0594
Liang X, Potter J, Kumar S, et al. Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J Biotechnol. 2015;208:44-53. doi:10.1016/j.jbiotec.2015.04.024
Nguyen DN, Roth TL, Li PJ, et al. Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency. Nat Biotechnol. 2020;38:44-49. doi:10.1038/s41587-019-0325-6
Zhang D, Wang G, Yu X, et al. Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy. Nat Nanotechnol. 2022;17:777-787. doi:10.1038/s41565-022-01122-3
Samaridou E, Heyes J, Lutwyche P. Lipid nanoparticles for nucleic acid delivery: current perspectives. Adv Drug Deliv Rev. 2020;154-155:37-63. doi:10.1016/j.addr.2020.06.002
Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2020;15:313-320. doi:10.1038/s41565-020-0669-6
Foss DV, Muldoon JJ, Nguyen DN, et al. Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes. Nat Biomed Eng. 2023;7:647-660. doi:10.1038/s41551-023-01032-2
Bothmer A, Gareau KW, Abdulkerim HS, et al. Detection and modulation of DNA translocations during multi-gene genome editing in T cells. CRISPR J. 2020;3:177-187. doi:10.1089/crispr.2019.0074
Adikusuma F, Piltz S, Corbett MA, et al. Large deletions induced by Cas9 cleavage. Nature. 2018;560:E8-E9. doi:10.1038/s41586-018-0380-z
Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol. 2018;36:765-771. doi:10.1038/nbt.4192
Stadtmauer EA, Fraietta JA, Davis MM, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367:eaba7365. doi:10.1126/science.aba7365
Koblan LW, Doman JL, Wilson C, et al. Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction. Nat Biotechnol. 2018;36:843-846. doi:10.1038/nbt.4172
Scholefield J, Harrison PT. Prime editing-an update on the field. Gene Ther. 2021;28:396-401. doi:10.1038/s41434-021-00263-9
Chow RD, Chen JS, Shen J, Chen S. A web tool for the design of prime-editing guide RNAs. Nat Biomed Eng. 2021;5:190-194. doi:10.1038/s41551-020-00622-8
Webber BR, Lonetree CL, Kluesner MG, et al. Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nat Commun. 2019;10:5222. doi:10.1038/s41467-019-13007-6
Diorio C, Murray R, Naniong M, et al. Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL. Blood. 2022;140:619-629. doi:10.1182/blood.2022015825
Glaser V, Flugel C, Kath J, et al. Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells. Genome Biol. 2023;24:1-21.
McAuley GE, Yiu G, Chang PC, et al. Human T cell generation is restored in CD3delta severe combined immunodeficiency through adenine base editing. Cell. 2023;186:1398-1416.e1323. doi:10.1016/j.cell.2023.02.027
Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16:566-581.
Lu Y, Xue J, Deng T, et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat Med. 2020;26:732-740. doi:10.1038/s41591-020-0840-5
Choi BD, Yu X, Castano AP, et al. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J Immunother Cancer. 2019;7:304. doi:10.1186/s40425-019-0806-7
Liu X, Zhang Y, Cheng C, et al. CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell Res. 2017;27:154-157. doi:10.1038/cr.2016.142
Yoshikawa T, Wu Z, Inoue S, et al. Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy. Blood. 2022;139:2156-2172. doi:10.1182/blood.2021012714
Shi L, Meng T, Zhao Z, et al. CRISPR knock out CTLA-4 enhances the anti-tumor activity of cytotoxic T lymphocytes. Gene. 2017;636:36-41. doi:10.1016/j.gene.2017.09.010
Zhang Y, Zhang X, Cheng C, et al. CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells. Front Med. 2017;11:554-562.
Tang N, Cheng C, Zhang X, et al. TGF-beta inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight. 2020;5:e133977. doi:10.1172/jci.insight.133977
Giuffrida L, Sek K, Henderson MA, et al. CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nat Commun. 2021;12:3236. doi:10.1038/s41467-021-23331-5
Freitas KA, Belk JA, Sotillo E, et al. Enhanced T cell effector activity by targeting the mediator kinase module. Science. 2022;378:eabn5647. doi:10.1126/science.abn5647
Jung IY, Kim YY, Yu HS, Lee M, Kim S, Lee J. CRISPR/Cas9-mediated knockout of DGK improves antitumor activities of human T cells. Cancer Res. 2018;78:4692-4703. doi:10.1158/0008-5472.CAN-18-0030
Bertaina A, Merli P, Rutella S, et al. HLA-haploidentical stem cell transplantation after removal of alphabeta+ T and B cells in children with nonmalignant disorders. Blood. 2014;124:822-826. doi:10.1182/blood-2014-03-563817
Tipanee J, Samara-Kuko E, Gevaert T, Chuah MK, VandenDriessche T. Universal allogeneic CAR T cells engineered with sleeping beauty transposons and CRISPR-CAS9 for cancer immunotherapy. Mol Ther. 2022;30:3155-3175. doi:10.1016/j.ymthe.2022.06.006
Kagoya Y, Guo T, Yeung B, et al. Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to Be used for adoptive T-cell therapy. Cancer Immunol Res. 2020;8:926-936. doi:10.1158/2326-6066.CIR-18-0508
Hu Y, Zhou Y, Zhang M, et al. CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2021;27:2764-2772. doi:10.1158/1078-0432.CCR-20-3863
Guo Y, Tong C, Su L, et al. CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma. Blood Adv. 2022;6:2695-2699. doi:10.1182/bloodadvances.2021006232
Stenger D, Stief TA, Kaeuferle T, et al. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR. Blood. 2020;136:1407-1418. doi:10.1182/blood.2020005185
Liao NS, Bix M, Zijlstra M, Jaenisch R, Raulet D. MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. Science. 1991;253:199-202. doi:10.1126/science.1853205
Gornalusse GG, Hirata RK, Funk SE, et al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat Biotechnol. 2017;35:765-772.
Li W, Zhu X, Xu Y, et al. Simultaneous editing of TCR, HLA-I/II and HLA-E resulted in enhanced universal CAR-T resistance to Allo-rejection. Front Immunol. 2022;13:1052717. doi:10.3389/fimmu.2022.1052717
Puig-Saus C, Sennino B, Peng S, et al. Neoantigen-targeted CD8(+) T cell responses with PD-1 blockade therapy. Nature. 2023;615:697-704. doi:10.1038/s41586-023-05787-1
Trefny MP, Kirchhammer N, Auf der Maur P, et al. Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy. Nat Commun. 2023;14:86. doi:10.1038/s41467-022-35583-w
Cortez JT, Montauti E, Shifrut E, et al. CRISPR screen in regulatory T cells reveals modulators of Foxp3. Nature. 2020;582:416-420. doi:10.1038/s41586-020-2246-4
Chow RD, Wang G, Ye L, et al. In vivo profiling of metastatic double knockouts through CRISPR-Cpf1 screens. Nat Methods. 2019;16:405-408. doi:10.1038/s41592-019-0371-5
Park JJ, Codina A, Ye L, et al. Double knockout CRISPR screen for cancer resistance to T cell cytotoxicity. J Hematol Oncol. 2022;15:172. doi:10.1186/s13045-022-01389-y
Han K, Jeng EE, Hess GT, Morgens DW, Li A, Bassik MC. Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions. Nat Biotechnol. 2017;35:463-474. doi:10.1038/nbt.3834
Dong MB, Tang K, Zhou X, et al. Cas12a/Cpf1 knock-in mice enable efficient multiplexed immune cell engineering. bioRxiv. 2023. doi:10.1101/2023.03.14.532657
Chow RD, Kim HR, Chen S. Programmable sequential mutagenesis by inducible Cpf1 crRNA array inversion. Nat Commun. 2018;9:1903. doi:10.1038/s41467-018-04158-z
Mathis N, Allam A, Kissling L, et al. Predicting prime editing efficiency and product purity by deep learning. Nat Biotechnol. 2023. doi:10.1038/s41587-022-01613-7
Rubin AJ, Parker KR, Satpathy AT, et al. Coupled single-cell CRISPR screening and epigenomic profiling reveals causal gene regulatory networks. Cell. 2019;176:361-376.e317. doi:10.1016/j.cell.2018.11.022
Chen KH, Boettiger AN, Moffitt JR, Wang S, Zhuang X. RNA imaging. Spatially resolved, highly multiplexed RNA profiling in single cells. Science. 2015;348:aaa6090. doi:10.1126/science.aaa6090
Coelho MA, Cooper S, Strauss ME, et al. Base editing screens map mutations affecting interferon-gamma signaling in cancer. Cancer Cell. 2023;41:288-303.e286. doi:10.1016/j.ccell.2022.12.009
Wagner DL, Peter L, Schmueck-Henneresse M. Cas9-directed immune tolerance in humans-a model to evaluate regulatory T cells in gene therapy? Gene Ther. 2021;28:549-559. doi:10.1038/s41434-021-00232-2
Ferdosi SR, Ewaisha R, Moghadam F, et al. Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes. Nat Commun. 2019;10:1842. doi:10.1038/s41467-019-09693-x
Schmid D, Park CG, Hartl CA, et al. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. Nat Commun. 2017;8:1747. doi:10.1038/s41467-017-01830-8
Cevaal PM, Ali A, Czuba-Wojnilowicz E, et al. In vivo T cell-targeting nanoparticle drug delivery systems: considerations for rational design. ACS Nano. 2021;15:3736-3753. doi:10.1021/acsnano.0c09514
Wang Z, Li N, Feng K, et al. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell Mol Immunol. 2021;18(9):2188-2198.
Feng KC, Guo YL, Liu Y, et al. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. J Hematol Oncol. 2017;10(1):4.
Dequeant ML, Sagert J, Kalaitzidis D, et al. Abstract 1537: CD70 knockout: a novel approach to augment CAR-T cell function. Cancer Res. 2021;81(suppl. 13):1537.
McGuirk JP, Tam CS, Kröger N, et al. CTX110 allogeneic CRISPR-Cas9-engineered CAR T cells in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): results from the phase 1 dose escalation carbon study. Blood. 2022;140(suppl. 1):10303-10306.
Zhang N, Si J, Li G, et al. Decreasing HPK1 expression in CD19 CAR-T cells: a novel strategy to overcome challenges of cell therapy for adult (r/r) B-ALL. Am Soc Clin Oncol. 2022.
Garner E, Degagne E, Roy S, et al. Abstract LB009: a BCMA-specific allogeneic CAR-T cell therapy (CB-011) genome-engineered to express an HLA-E fusion transgene to prevent immune cell rejection. Cancer Res. 2022;82(suppl. 12):LB009.
Dar H, Henderson D, Padalia Z, et al. Preclinical development of CTX120, an allogeneic CAR-T cell targeting Bcma. Blood. 2018;132(suppl. 1):1921.
Stadtmauer EA, Cohen AD, Weber K, et al. First-in-human assessment of feasibility and safety of multiplexed genetic engineering of autologous T cells expressing NY-ESO-1 TCR and CRISPR/Cas9 gene edited to eliminate endogenous TCR and PD-1 (NYCE T cells) in advanced multiple myeloma (MM) and sarcoma. Blood. 2019;134(suppl. 1):49.
Wei J, Yan J, Su S, et al. A phase I/II trial of CRISPR-Cas9-mediated PD-1 knockout Epstein-Barr virus cytotoxic lymphocytes (EBV-CTLs) for advanced stage EBV associated malignancies-trial in progress. Ann Oncol. 2018;29:v36.
O'Brien S, Nastoupil LJ, Essell J, et al. A first-in-human phase 1, multicenter, open-label study of CB-010, a next-generation CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout, in patients with relapsed/refractory B cell non-Hodgkin lymphoma (ANTLER study). Blood. 2022;140(suppl. 1):9457-9458.
Pal S, Tran B, Haanen J, et al. 558 CTX130 allogeneic CRISPR-Cas9-engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: results from the phase 1 COBALT-RCC study. J ImmunoTher Cancer. 2022;10(suppl. 2):A584.
Cossette D, Aiyer S, Kimball C, et al. Clinical-scale production and characterization of Ntla-5001-a novel approach to manufacturing CRISPR/Cas9 engineered T cell therapies. Blood. 2021;138:3881.
Ottaviano G, Georgiadis C, Gkazi SA, et al. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Sci Transl Med. 2022;14(668):eabq3010.